amh | 24748
Mullerian inhibiting hormone (AMH)
Keywords
AMH, ART (Assisted Reproductive Technologies), Cycle, Fertility, Hormones woman, ICSI, Infertility, IVF, Menopause, Mullerian inhibiting, Reproductive medicine, Spermogram, Sterility
| Material |
|
|
| Min. quantity | 500 µL | |
| Stability | 1 day / 18-25°C; 6 days / 2-8°C; 2 months / -20°C | |
| Duration | 1 day | |
| Frequency | 7 x per week | |
| Method | Chemiluminescent Immuno Assay | |
| Price | CHF 78.30 | |
| Tariff | 78.30 TP | |
| LA position | 1474.10 | |
| Designation | Zytokine/Adhäsionsmoleküle/-Rezeptoren/- |
Reference values
| Value | Age | Sex |
|---|---|---|
| < 24.3 pmol/L | 0 - 60 D | f |
| 4.5 - 29.5 pmol/L | 3 - 3 M | f |
| 3.0 - 18.9 pmol/L | 4 - 12 M | f |
| 1.9 - 39.2 pmol/L | 1 - 4 Y | f |
| 5.5 - 57.1 pmol/L | 5 - 8 Y | f |
| 4.7 - 60.1 pmol/L | 9 - 17 Y | f |
| 6.8 - 95.2 pmol/L | 18 - 25 Y | f |
| 1.2 - 52.7 pmol/L | 26 - 30 Y | f |
| 0.5 - 52.5 pmol/L | 31 - 35 Y | f |
| 0.2 - 51.0 pmol/L | 36 - 40 Y | f |
| < 23.5 pmol/L | 41 - 45 Y | f |
| < 8.3 pmol/L | >= 46 Y | f |
| 107.9 - 1903.5 pmol/L | 0 - 60 D | m |
| 5.2 - 114.6 pmol/L | >= 19 Y | m |
| cycle:7.1 - 57 pmol/L | >= 13 Y | f |
| menopause:< 7.1 pmol/L | >= 13 Y | f |
| cycle:12 - 38 pmol/L | >= 15 Y | f |
| menopause:< 3 pmol/L | >= 15 Y | f |
| Ovar. Reserve: pmol/L | >= 18 Y | f |
| Limited:< 9 pmol/L | >= 18 Y | f |
| Adequate:9 - 50 pmol/L | >= 18 Y | f |
| PCOS possible:>50 pmol/L | >= 18 Y | f |
| :Puberty stages pmol/L | 0 - 18 Y | m |
| :according to Tanner: pmol/L | 0 - 18 Y | m |
| P1:35.4 - 1031.6 pmol/L | 0 - 18 Y | m |
| P2:35.9 - 1000.0 pmol/L | 0 - 18 Y | m |
| P3:18.6 - 541.9 pmol/L | 0 - 18 Y | m |
| P4:3.0 - 143.8 pmol/L | 0 - 18 Y | m |
| P5:13.9 - 151.4 pmol/L | 0 - 18 Y | m |
| Prepubertal:27-1141 pmol/L | 0 - 25 Y | m |
| adult:4.1 - 75.7 pmol/L | m | |
| :Puberty stages pmol/L | 8 - 18 Y | m |
| :according to Tanner: pmol/L | 8 - 18 Y | m |
| P1:35.4 - 1031.6 pmol/L | 8 - 18 Y | m |
| P2:35.9 - 1000.0 pmol/L | 8 - 18 Y | m |
| P3:18.6 - 541.9 pmol/L | 8 - 18 Y | m |
| P4:3.0 - 143.8 pmol/L | 8 - 18 Y | m |
| P5:13.9 - 151.4 pmol/L | 8 - 18 Y | m |
| :Puberty stages pmol/L | 10 - 18 Y | m |
| :according to Tanner: pmol/L | 10 - 18 Y | m |
| P1:35.4 - 1031.6 pmol/L | 10 - 18 Y | m |
| P2:35.9 - 1000.0 pmol/L | 10 - 18 Y | m |
| P3:18.6 - 541.9 pmol/L | 10 - 18 Y | m |
| P4:3.0 - 143.8 pmol/L | 10 - 18 Y | m |
| P5:13.9 - 151.4 pmol/L | 10 - 18 Y | m |
| adult:10.7 - 31 pmol/L | >= 13 Y | m |
Team of consultants
|
MD
Uta Deus
FMH General internal medicine, FAMH Specialist in laboratory medicine
|
FMH General internal medicine, FAMH Specialist in laboratory medicine | T |
|
|
PhD
Maurus Curti
FAMH Specialist in laboratory medicine
|
FAMH Specialist in laboratory medicine | T |
|
|
Dr. sc. nat.
Corinne Ruppen
FAMH Specialist in laboratory medicine, main field clinical chemistry
|
FAMH Specialist in laboratory medicine, main field clinical chemistry | T |
|
|
Dr. rer. nat.
Kristina Vollmer
FAMH Specialist in laboratory medicine, main field clinical chemistry
|
FAMH Specialist in laboratory medicine, main field clinical chemistry | T |
|